^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CA9 expression

i
Other names: CA9, Carbonic Anhydrase 9, Carbonic Anhydrase IX, Renal Cell Carcinoma-Associated, Antigen G250, RCC-Associated Protein G250, RCC-Associated Antigen G250, Carbonate Dehydratase IX, Carbonic Dehydratase, Membrane Antigen MN, P54/58N, CA-IX, CAIX, G250
Entrez ID:
Related biomarkers:
8d
Dectin-1/SYK Activation Induces Antimicrobial Peptide and Negative Regulator of NF-κB Signaling in Human Oral Epithelial Cells. (PubMed, In Vivo)
Oral epithelial cells express Dectin-1 and recognize β-glucan, which activates SYK and induces the expression of antimicrobial peptides and negative regulators of NF-κB, potentially maintaining oral homeostasis.
Journal
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • S100A8 (S100 Calcium Binding Protein A8) • TNFAIP3 (TNF Alpha Induced Protein 3) • S100A9 (S100 Calcium Binding Protein A9) • SYK (Spleen tyrosine kinase) • CA9 (Carbonic anhydrase 9) • CLEC7A (C-Type Lectin Domain Containing 7A) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
|
CA9 expression • S100A9 expression
10d
Identification of novel CA IX inhibitor: Pharmacophore modeling, docking, DFT, and dynamic simulation. (PubMed, Comput Biol Chem)
The current study has led to the discovery of lead compounds that show considerable promise as hCA IX inhibitors and suggests that three compounds with special molecular features are more likely to be better-inhibiting hCA IX. Compound S35, characterized by a higher stability margin and a smaller energy gap in quantum studies, is an ideal candidate for selective inhibition of CA IX.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
11d
Modern view on the problem of diagnostics of renal angiomioadenomatous tumor (PubMed, Urologiia)
Our results allow to state that angiomyoadenomatous tumor and clear cell papillary renal cell tumor are different neoplasms.
Journal
|
CDH1 (Cadherin 1) • CA9 (Carbonic anhydrase 9) • PAX8 (Paired box 8) • CDC42EP3 (CDC42 Effector Protein 3)
|
CA9 expression
11d
Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer. (PubMed, Cancer Genomics Proteomics)
Genes reported herein may be effective biomarkers to identify TNBC patients who will and will not benefit from immunotherapy and may be particularly important genes for developing future treatment strategies, including immunotherapy.
Journal • IO biomarker • Immune cell
|
IFNG (Interferon, gamma) • CA9 (Carbonic anhydrase 9) • CD3D (CD3d Molecule) • ENO1 (Enolase 1) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • PRKCB (Protein Kinase C Beta) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • STAT4 (Signal Transducer And Activator Of Transcription 4) • ARHGAP30 (Rho GTPase Activating Protein 30)
|
CA9 expression
1m
Differential carbonic anhydrase activities control EBV-induced B-cell transformation and lytic cycle reactivation. (PubMed, PLoS Pathog)
In contrast, during lytic cycle reactivation CA9 expression is transcriptionally suppressed by the key EBV lytic cycle transactivator, BZLF1 through its transactivation domain. Overall, our study highlights the dynamic alterations of CA9 expression and its activity in regulating pH homeostasis act as one of the major drivers for EBV induced B-cell transformation and subsequent B-cell lymphomagenesis.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2ms
Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX. (PubMed, J Nucl Med)
[177Lu]Lu-DPI-4452 demonstrated strong tumor growth inhibition in 2 xenograft mouse models. Thus, the 2 agents potentially provide a theranostic approach for selecting and treating patients with CAIX-expressing tumors such as ccRCC, CRC, and pancreatic ductal adenocarcinoma.
Preclinical • Journal
|
VHL (von Hippel-Lindau tumor suppressor) • CA9 (Carbonic anhydrase 9)
|
VHL mutation • CA9 overexpression • CA9 expression
|
Debio 0228
2ms
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. (PubMed, Mol Cancer)
A Tet-On doxycycline-inducible CAIX expressing cell line was established to mimic various CAIX densities, providing coverage from CAIX-high skrc-59 tumor cells to CAIX-low MMNK-1 cholangiocytes...Moreover, in an RCC orthotopic mouse model, G9 CAR-T cells showed enhanced tumor control compared to G250. In summary, G9 has successfully mitigated OTOT side effects and in doing so has made CAIX a druggable immunotherapeutic target.
Journal • Adverse events • CAR T-Cell Therapy • IO biomarker
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2ms
Design, synthesis and mechanism study of coumarin-sulfonamide derivatives as carbonic anhydrase IX inhibitors with anticancer activity. (PubMed, Chem Biol Interact)
Mechanistic investigation using western blotting revealed compound 8q exerted the anti-migrative and anti-invasive effects probably through mitochondria-mediated PI3K/AKT pathway by targeting CAIX. In summary, coumarin-3-sulfonamide derivatives were developed as potential and effective CAIX inhibitors, which were worthy of further investigation.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2ms
Downregulation of carbonic anhydrase IX expression in mouse xenograft nasopharyngeal carcinoma model via doxorubicin nanobubble combined with ultrasound. (PubMed, Open Med (Wars))
DOX-NB combined with DUS irradiation can downregulate the expression of CAIX in mouse xenograft NPC model. This may be due to the synergistic effect of DUS combined with DOX-NB in reducing MVD in NPC.
Preclinical • Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2ms
Intra-abdominal epithelioid neoplasm with EWSR1::CREB fusions involving the kidney: A clinicopathologic and molecular characterization with an emphasis on differential diagnosis. (PubMed, Mod Pathol)
On follow-up, 1 patient developed multiple spinal bone metastases 5 months after the surgery while the other two patients were free of disease 9 and 120 months after diagnosis, respectively. Our findings demonstrate that intra-abdominal epithelioid neoplasms with EWSR1::CREB fusions may rarely occur primarily in the kidney and should be included in the differential diagnosis of primary renal epithelioid mesenchymal neoplasms.
Journal
|
EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • CA9 (Carbonic anhydrase 9) • FUS (FUS RNA Binding Protein) • MUC4 (Mucin 4, Cell Surface Associated) • ATF1 (Activating Transcription Factor 1) • CREB1 (CAMP Responsive Element Binding Protein 1) • CREM (CAMP Responsive Element Modulator)
|
MUC4 expression • CA9 expression
2ms
LINC02086 inhibits ferroptosis and promotes malignant phenotypes of pancreatic cancer via miR-342-3p/CA9 axis. (PubMed, Funct Integr Genomics)
Taken together, LINC02086 upregulates CA9 expression by competitively binding with miR-342-3p, thereby inhibiting ferroptosis in PC cells and promoting their malignant phenotype. The results of our study provide new insights into how LINC02086 contributes to the progression of PC.
Journal
|
CA9 (Carbonic anhydrase 9) • MIR342 (MicroRNA 342)
|
CA9 expression
2ms
Radiotheranostics Based on Chemical Control of Radioactivity Pharmacokinetics (PubMed, Yakugaku Zasshi)
In addition to PSMA, this platform for radiotheranostics has also shown efficacy against various cancer target molecules, including carbonic anhydrase IX (CA-IX), which is highly expressed in hypoxic regions of cancer, and glucagon-like peptide-1 receptor (GLP-1R), which is highly expressed in insulinomas. This review presents these recent results of our studies on radiotheranostics for cancer.
PK/PD data • Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2ms
BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines. (PubMed, Anticancer Res)
The study suggests that the application of novel BET PROTACs in combination with chemotherapeutics could represent a new therapeutic option to improve the therapy of osteosarcomas. First orally available PROTACs have reached clinical trials.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • AXL (AXL Receptor Tyrosine Kinase) • BCL2L1 (BCL2-like 1) • CDH1 (Cadherin 1) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin) • BRD4 (Bromodomain Containing 4)
|
HER-2 expression • CDH1 expression • VIM expression • CA9 expression • EPCAM expression
|
cisplatin • gemcitabine • doxorubicin hydrochloride • JQ-1 • topotecan • ARCC-29
2ms
Immunophenotypes and Tumor Immune Microenvironment in Hepatocellular Carcinoma With Macrotrabecular Massive and Vessels Encapsulating Tumor Clusters. (PubMed, In Vivo)
MTM-HCC had different immunophenotypes and TIMEs compared to HCC with the VETC pattern. Although both had immunosuppressive TIME, the elements forming TIME were quite different. To enhance the immune checkpoint inhibitor efficacy, changing TIME from a suppressive to an active form is essential.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • KRT19 (Keratin 19)
|
PD-L1 expression • CA9 expression
2ms
Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX. (PubMed, Chem Sci)
This new H2MacropaSqOEt chelator was used to modify a monoclonal antibody, girentuximab (hG250), that binds to carbonic anhydrase IX, an enzyme that is overexpressed on the surface of cancers such as clear cell renal cell carcinoma...Evaluation of [225Ac]Ac(MacropaSq-hG250) in a mouse xenograft model, that overexpresses carbonic anhydrase IX, demonstrated a highly significant therapeutic response. It is likely that H2MacropaSqOEt could be used to modify other antibodies providing a readily adaptable platform for other actinium-225 based therapeutics.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 overexpression • CA9 expression
|
Rencarex (girentuximab)
2ms
Vascular, adipose tissue, and/or calyceal invasion in clear cell tubulopapillary renal cell tumour: potentially problematic diagnostic scenarios. (PubMed, Histopathology)
These overall findings continue to support the benign designation for clear cell tubulopapillary renal cell tumours, despite morphologic features that might raise the possibility of a 'higher stage' neoplasm.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2ms
Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology. (PubMed, J Ethnopharmacol)
QZACP inhibits HCC by reducing the expression of STAT3, VEGFA, JUN, FGF2, BCL2L1, AR, TERT, MMP7, MMP1, ABCB1, CA9, and ESR2. DAAME may be an important active component of QZACP for the prevention and treatment of HCC, inhibiting it by targeting the expression of CA9.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • BCL2L1 (BCL2-like 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CA9 (Carbonic anhydrase 9) • FGF2 (Fibroblast Growth Factor 2) • MMP1 (Matrix metallopeptidase 1) • MMP7 (Matrix metallopeptidase 7)
|
BCL2 expression • STAT3 expression • CA9 expression
2ms
Hypoxia-related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis. (PubMed, Cancer Sci)
Moreover, coculturing with RENCA/hCA9 cells more actively prompted T cell apoptosis than with RENCA cells. Collectively, these findings suggest hypoxia-associated CA9 not only boosts serpinB9 in cancer cells but also synergistically intensifies T cell apoptosis via acidosis, characterizing RENCA/hCA9 tumors as "cold."
Journal
|
CA9 (Carbonic anhydrase 9) • GZMB (Granzyme B) • SERPINB9 (Serpin Family B Member 9)
|
CA9 expression
3ms
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells (clinicaltrials.gov)
P=N/A, N=877, Active, not recruiting, GOG Foundation | Phase classification: P1 --> P=N/A
Phase classification
|
CA9 (Carbonic anhydrase 9) • MCM2 (Minichromosome maintenance complex component 2)
|
CA9 expression
3ms
A comparative study of diaryl urea molecules with and without sulfonamide group on Carbonic anhydrase IX and XII inhibition and its consequence on breast cancer cells. (PubMed, Bioorg Chem)
The IC50 values of J16 for MDA-MB-231 and MCF-7 cells, under normoxic condition were 6.3 and 3.7 µM respectively, which are 1.9/3.3 and 15.8 times better than U-4-Nitro and SLC-0111 respectively...Expression of the other apoptosis markers Bcl-2, Bim, caspase 9 and caspase 3 substantiated the apoptosis mechanism. However, decreased transcription/expression of HIF1A/HIF-1α and hCA-IX/XII also implies the inhibition of the extracellular signal-regulated kinase pathway by J2 and J16.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CA9 (Carbonic anhydrase 9) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • CCND1 expression • HIF1A expression • CA9 expression
|
SLC-0111
3ms
Journal • Metastases
|
CD34 (CD34 molecule) • CA9 (Carbonic anhydrase 9)
|
CA9 expression
3ms
Construction and Evaluation of a Nanosystem that Combines Acidification Promoted Chemodynamic Therapy and Intracellular Drug Release Monitoring. (PubMed, J Biotechnol)
The two polymers were employed to construct the doxorubicin (DOX) and ferrocene (Fc) co-loaded P-CAIDF/PT NPs through the film dispersion method...Moreover, P-CAIDF/PT also monitored the intracellular drug release processes through the fluorescence resonance energy transfer (FRET) effect depending on the inherent DOX/TPE pair. In conclusion, the P-CAIDF/PT nanosystem can achieve the combination therapy of acidification-enhanced CDT and chemotherapy as well as therapy monitoring, thus providing new ideas for the design and development of TNBC therapeutic agents.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 overexpression • CA9 expression
|
doxorubicin hydrochloride
3ms
Synthesis, Characterization, Cytotoxicity, Cellular Imaging, Molecular Docking, and ADMET Studies of Piperazine-Linked 1,8-Naphthalimide-Arylsulfonyl Derivatives. (PubMed, Int J Mol Sci)
In silico studies, including molecular docking, molecular dynamics (MD) simulation, and ADME/Tox results, indicated that the compounds had the ability to target CAIX-expressing cancers. These findings suggest that piperazine-linked 1,8-naphthalimide-arylsulfonyl derivatives are potential candidates for cancer theranostics and a valuable backbone for future research.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
4ms
Ligand based pharmacophore modelling and integrated computational approaches in the quest for small molecule inhibitors against hCA IX. (PubMed, RSC Adv)
The top 4 compounds in the molecular dynamics simulation studies for 100 ns provided useful insights on the stability of the complex and the DFT studies confirmed the energy variation between HOMO and LUMO is within an acceptable range. An average binding score of -7.8 Kcal mol for the lead compounds and high stability margin in the dynamics study concludes that these lead compounds demonstrated outstanding potential for hCA IX inhibitory action theoretically and that further experimental studies for selective inhibition are inevitable.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
4ms
Preclinical Evaluation of virus-like particle Vaccine Against Carbonic Anhydrase IX Efficacy in a Mouse Breast Cancer Model System. (PubMed, Mol Biotechnol)
This vaccine was tested in a therapeutic setting by using a triple-negative breast cancer mouse model system comprising 4T1, 4T1-Car9 and 4T1-Car9 cells, the latter representing positive and negative controls for murine CAIX production, respectively. The humoural immune responses induced in tumour-bearing animals were predominantly of Th1-type and higher anti-mCAIXc titres correlated with slower growth and lung metastasis development of 4T1 tumours constitutively expressing mCAIX in vivo in the syngeneic host.
Preclinical • Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
4ms
LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma. (PubMed, Cell Death Dis)
Together, these results expand our understanding of the cancer-associated function of lncRNAs, highlighting the ZNF674-AS1/IGF2BP3/CA9 axis as a constituting regulatory mode in NB tumor growth and cisplatin resistance. These insights reveal the pivotal role of ZNF674-AS1 inhibition in recovering cisplatin sensitivity, thus providing potential therapeutic targets for NB treatment.
Journal
|
CA9 (Carbonic anhydrase 9) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
CA9 expression • IGFBP3 elevation
|
cisplatin
4ms
Immunohistochemical expression of cytochrome P4A11 (CYP4A11), carbonic anhydrase 9 (CAIX) and Ki67 in renal cell carcinoma; diagnostic relevance and relations to clinicopathological parameters. (PubMed, Pathol Res Pract)
CYP4A11 and CAIX can be used as diagnostic markers to differentiate clear cell RCC from other subtypes. CYP4A11 is more diagnostically accurate and specific than CAIX. High expression of CYP4A11, low CAIX expression and high ki67 labeling index were related to features of aggressive tumor behavior.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
4ms
Clinicopathological, Immunohistochemical, and Molecular Characteristics of Pigmented Microcystic Chromophobe Renal Cell Carcinoma with Favorable Prognosis. (PubMed, Int J Surg Pathol)
Pigmented microcystic chromophobe RCC has a relatively benign biological behavior, and distant metastases and sarcomatoid transformation are rare. This overview of five additional tumors of pigmented microcystic chromophobe RCC offers further insight into this special subtype of chromophobe RCC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • RAD50 (RAD50 Double Strand Break Repair Protein) • GLI1 (GLI Family Zinc Finger 1) • TFE3 • CA9 (Carbonic anhydrase 9) • KRT7 (Keratin-7) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • VIM (Vimentin) • MLANA (Melan-A) • GATA3 (GATA binding protein 3) • KRT20 (Keratin 20) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2) • CLDN7 (Claudin 7) • LRRK2 (Leucine Rich Repeat Kinase 2)
|
CDH1 expression • VIM expression • CA9 expression
4ms
Bifunctional drug delivery system with carbonic anhydrase IX targeting and glutathione-responsivity driven by host-guest amphiphiles for effective tumor therapy. (PubMed, Carbohydr Polym)
In this work, a supramolecular host (L-CD) with targeting function based on a β-cyclodextrin (β-CD) backbone was synthesized with carbonic anhydrase IX (CAIX) overexpressed on tumor cells as a target, and the methotrexate prodrug (MTX-SS-Ad) modified by adamantane and disulfide bond was prepared to be used as the guest...Moreover, SNP can effectively inhibit the proliferation of cancer cells without generating additional toxic side effects on normal cells. So, we provide a strategy of bifunctional drug delivery system with targeting and glutathione-responsivity for effective tumor therapy.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 overexpression • CA9 expression
|
methotrexate
5ms
Synthesis, biological evaluation and molecular docking studies of novel 1,3,4-thiadiazoles as potential anticancer agents and human carbonic anhydrase inhibitors. (PubMed, Mol Divers)
The results indicated that compound 4e showed higher efficacy than standard acetazolamide (IC = 0.58 ± 0.02 µM) with an IC value of 0.03 ± 0.01 µM. Furthermore, molecular docking studies were carried out using carbonic anhydrase IX crystals to determine the compound's interactions with the enzyme's active sites. This comprehensive investigation sheds light on the intricate interplay between molecular structure and biological activity, providing valuable insights into the therapeutic potential of these compounds.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CA9 (Carbonic anhydrase 9) • CASP3 (Caspase 3)
|
BCL2 expression • CA9 expression
|
acetazolamide
5ms
Synchronous Double Primary Malignant Tumors and their Possible Shared Genes: A Rare Clinical Entity. (PubMed, Curr Med Imaging)
18F-FDG PET/CT combined with contrast-enhanced CT is an effective diagnostic tool in evaluating synchronous CRC and RCC. By analyzing this clinical case and conducting bioinformatic analysis, we improved our current understanding of the mechanisms underlying synchronous tumors.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
5ms
Co-vulnerabilities of inhibiting carbonic anhydrase IX in ferroptosis-mediated tumor cell death. (PubMed, Front Mol Biosci)
Many studies in multiple solid tumour models have demonstrated that targeting CAIX activity with the selective CAIX/XII inhibitor, SLC-0111, results in anti-tumour efficacy, particularly when used in combination with chemotherapy or immune checkpoint blockade, and has now advanced to the clinic...Importantly, the data from these models demonstrates that CAIX inhibition may sensitize tumour cells to cytotoxic drugs and evidence now points to ferroptosis, an iron-dependent form of regulated cell death (RCD) that results from accumulation of toxic levels of phospholipid peroxidation as a major mechanism involved in CAIX-mediated sensitization to cancer therapy. In this mini-review, we discuss recent advances demonstrating the mechanistic role CAIX plays in sensitizing cancer cells to ferroptosis.
Review • Journal • Tumor cell
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
|
SLC-0111
5ms
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. (ASCO-GU 2024)
Concerning their first-line metastatic treatment, 67 (89%) had received Sunitinib, and 8 (11%) had received Everolimus. These results reinforce clinical data on the expected benefit of immunotherapy in metastatic pRCC treatment, as PD-L1 expression is a factor of poor prognosis in our multicenter cohort.
Retrospective data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CA9 (Carbonic anhydrase 9)
|
PD-L1 expression • LAG3 expression • CA9 expression • PD-L2 expression
|
sunitinib • everolimus
5ms
Development of AB-2100, an autologous integrated circuit T (ICT) cell therapy targeting CA9 intended for the treatment of ccRCC. (ASCO-GU 2024)
These data demonstrate that AB-2100 selectively targets tumors co-expressing PSMA and CA9, and can overcome multiple suppressive mechanisms in the TME. These results support the evaluation of AB-2100 in the clinic for the treatment of advanced or metastatic ccRCC.
IO biomarker
|
TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CA9 (Carbonic anhydrase 9)
|
FOLH1 expression • CA9 expression
|
AB-2100
5ms
First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma. (ASCO-GU 2024)
[68Ga]Ga-DPI-4452 provides exceptional images in patients with ccRCC without clinically significant toxicity. Very high SUVs and tumor-to-background ratios suggest potential for use in both diagnostics and patient selection for therapy. The tumor retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy.
Clinical • P1 data
|
CA9 (Carbonic anhydrase 9)
|
CA9 overexpression • CA9 expression
|
Debio 0228
5ms
Selective Tumor Hypoxia Targeting Using M75 Antibody Conjugated Photothermally Active MoO Nanoparticles. (PubMed, ACS Omega)
The key to effective cancer treatment may be the synergistic employment of active targeting and noninvasive, tumor-selective therapeutic approaches, such as nanoscale-mediated PTT. The use of active targeting can streamline nanoparticle delivery increasing photothermal yield and therapeutic success.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
5ms
Prognostic value of hypoxia-responsive gene expression profile in patients diagnosed with head and neck squamous cell carcinoma. (PubMed, Transl Oncol)
Additionally, low expression of KIF14 mRNA correlated with significantly shorter OS (overall survival). In conclusion, our results suggest that KIF14 might be a useful prognostic and predictive marker in HNSCC.
Journal • Gene Expression Profile
|
EREG (Epiregulin) • CA9 (Carbonic anhydrase 9) • SERPINE1 (Serpin Family E Member 1) • CCNB1 (Cyclin B1)
|
CA9 expression • SERPINE1 expression
6ms
Synthesis of new class of non-sulfonamide bis-benzimidazoles as antitumor agents by inhibiting carbonic anhydrase-IX enzyme. (PubMed, Int J Biol Macromol)
Their inhibitory potential for human CA-IX (hCA-IX) was evaluated in-vitro, where several synthesized derivatives showed potent inhibition of hCA-IX (IC values in range of 5.23 ± 1.05 to 40.10 ± 1.78 μM) and compounds 3-5, 7-8, 13-16, 21 and 23 showed superior activity than the standard drug "acetazolamide" (IC = 18.24 ± 1.43 μM)...Moreover, molecular docking was carried out to predict their binding modes in the active site of CA-IX and revealed a significant role of imidazole ring of synthesized entities in their effective binding with the specific residues of CA-IX. The obtained results paved the way for further in vivo and other pharmacological studies for the optimization of these molecules as possible anti-cancer agents.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
|
acetazolamide
6ms
Cancer Metastasis Prediction and Genomic Biomarker Identification through Machine Learning and eXplainable Artificial Intelligence in Breast Cancer Research. (PubMed, Diagnostics (Basel))
The findings of this study may prevent disease progression and metastases and potentially improve clinical outcomes by recommending customized treatment approaches for BC patients.
Journal • Machine learning
|
CA9 (Carbonic anhydrase 9) • PRAME (Preferentially Expressed Antigen In Melanoma) • SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2) • TSPYL5 (TSPY Like 5)
|
CA9 expression